Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Colorado Health Reporter.
Press releases published on August 1, 2025
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DALLAS, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the …
SmartVascular Dx™ Test Elevates Vascular Risk Detection in the Northeast & Partnership with MOMS
IRVINE, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- MorningStar Laboratories, LLC., (“MSL” or “the Company”), a leading developer of precision diagnostic tests addressing unmet clinical needs, is excited to announce that its SmartVascular Dx™ (SVDx) test, …
Sirona Biochem Update to Shareholders on Financial Status and Operations
VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (“Sirona”) wishes to provide shareholders with a critical update on the company’s financial position and recent corporate developments. The …
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, …
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the recent …
Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2025
Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2025 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR …
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted four newly-hired employees options to purchase an …
Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the closing of its underwritten …
Tevogen Bio to Accept $1 Million Additional Grant Funding for AI Expansion
Funds will support advancement of Tevogen.AI, the Company’s artificial intelligence–driven drug discovery initiative. The $1 million is part of up to $10 million in previously announced non‑dilutive grant funding from KRHP LLC. WARREN, N.J., Aug. 01, 2025 …
Global Outpatient Clinics Market Sees Shift Toward Tech-Driven Patient Care
Boston, Aug. 01, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, the “Global Outpatient Clinics Market” is expected to grow from $4.4 trillion in 2024 to $6.3 trillion by the end of 2029, at a compound annual growth rate (CAGR) of …
Pheton Holdings Ltd Issues Statements Addressing Recent Market Activity and Misleading Rumors
BEIJING, China, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Pheton Holdings Ltd (the “Company,” “we,” “our” or “Pheton”), a healthcare solution provider specializing in treatment planning systems for brachytherapy and other related products and services, today …
Carlsmed’s aprevo® Personalized Interbody Implants Receive CMS New Technology Add-On Payment (NTAP) for Cervical Fusion Procedures
CARLSBAD, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (“Carlsmed”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that in the Hospital Inpatient Prospective Payment Systems Final Rule …
Nexalin Technology Appoints Highly Experienced Financial Leader Justin Van Fleet as CFO to Support Nexalin’s Next Phase of Growth and Strategic Initiatives
HOUSTON, TX, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the appointment of Justin Van Fleet, CPA, …
Milestone Scientific Appoints Eric C. Hines as Chief Executive Officer
ROSELAND, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the appointment of Eric C. Hines as Chief …
IRADIMED CORPORATION Reports Record Second Quarter 2025 Financial Results
Announces Regular Quarterly Cash Dividend of $0.17 Per Share Raises Full Year 2025 Revenue and Earnings Guidance Reports record revenue of $20.4 million for the second quarter of 2025, an increase of $2.5 million, or 14%, compared to the same period in …
Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma
Lymphodepletion Regimen Selection Made in Conjunction with the ALPHA3 Data and Safety Monitoring Board (DSMB) and Steering Committee, and in Consultation with the FDA Following an ALLO-647-Related Death in the FCA (FC plus ALLO-647) Lymphodepletion Arm …
OrthoPediatrics Corp. Launches 3P™ Pediatric Plating Platform™ Hip System and Completes First Case
WARSAW, Ind., Aug. 01, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the US launch and first surgical case …
I-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary Shares
ROCKVILLE, Md., Aug. 01, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced the pricing of an …
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 55,450 restricted …